Lawrence Lamb
Company: IN8Bio
Job title: Chief Scientific Officer & Executive Vice President
Seminars:
Audience Led Discussion: Pushing Pipeline into the Clinic 2:00 pm
Establishing a comprehensive understanding of the regulatory landscape for allogeneic off-the-shelf gamma delta T cell therapies Covering key aspects such as regulatory considerations for the future, prepping for a BLA, IND filing procedures and overall navigating the journey from IND filing to getting into the clinic Open mic for direct questions with industry KOLsRead more
day: Conference Day Two - Track B - PM
Regulatory Overview on Past & Present Gamma Delta T Cell Therapies 1:30 pm
An overview on the current regulatory landscape for allogeneic therapies and discussing any anticipated changes and trends in the regulatory environment for future allogeneic therapies Exploration of potential challenges and opportunities in the evolving regulatory landscape and discussing how to use adaptive strategies to address regulatory uncertaintiesRead more
day: Conference Day Two - Track B - PM
Panel Discussion: Reflecting on a Year of Industry Advances: Key Insights from 2023 & Anticipating the Path Ahead in 2024 9:00 am
Reviewing latest clinical updates and identifying key areas of opportunities in the past year Discussing the race to clinic and attracting investors to fund scale ups into the clinic Considering current gamma delta t therapies to drive solid tumor success What does 2024 look like for the field and where is it headed?Read more
day: Conference Day One
Clinical Review Session: Unveiling the Enigma: Exploring Past & Present Clinical Insights into Gamma Delta Cells 9:00 am
An extensive break down of past and present clinical trials that have mapped the field of gamma delta T cells. From here we are able to identify definitive reasoning behind successes and failures and how this will predict what the future of gamma delta T therapies will look like. Delve into historical milestones and breakthroughs…Read more
day: Pre-Conference Day